DrugPatentWatch Archives

You are currently viewing the 2001 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: corticotropin

Summary for Generic Name: corticotropin

Drug Master File Entries: see list10

Clinical Trials for: corticotropin

ACTHar in the Treatment of Lupus Nephritis
Status: Recruiting Condition: Lupus Nephritis

Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations
Status: Completed Condition: Multiple Sclerosis (MS)

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
Status: Recruiting Condition: Diabetic Nephropathy

Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Status: Not yet recruiting Condition: Dermatomyositis; Juvenile Dermatomyositis

A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis
Status: Active, not recruiting Condition: Amyotrophic Lateral Sclerosis

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
Status: Recruiting Condition: Proteinuria; Idiopathic Membranous Nephropathy

Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.
Status: Recruiting Condition: Rheumatoid Arthritis

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Status: Recruiting Condition: Dermatomyositis; Polymyositis

Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease
Status: Recruiting Condition: Systemic Lupus Erythematosus (SLE)

The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients
Status: Recruiting Condition: Rheumatoid Arthritis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
corticotropin-zinc hydroxide
Injectable; Injection009854Approved prior to Jan 1, 1982DISCNNo<disabled><disabled>
Injectable; Injection007504Approved prior to Jan 1, 1982DISCNNo<disabled><disabled>
Organics Lagrange
Injectable; Injection010831Approved prior to Jan 1, 1982RXNo<disabled><disabled>
Injectable; Injection008975Approved prior to Jan 1, 1982DISCNNo<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology